GRFS

Grifols S.A.

Price

$8.20

return (12m)

-11.58%

p/e

10.59

p/bv

0.61

DIVIDEND YIELD

0.93%

GRFS price

Grifols

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment GRFS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

12.11%

3 months

5.44%

1 year

-11.58%

2 years

-3.09%

5 years

-35.66%

10 years

-35.06%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals GRFS

Valuation

P/E

10.59

Sector -3.14

Industry -3.14

P/BV

0.61

Sector 1.75

Industry 1.75

P/Revenue (PSR)

0.65

Sector 1.94

Industry 1.94

EV/EBITDA

7.14

Sector -204.21

Industry -204.21

EV/EBIT

9.88

Sector -41.36

Industry -41.36

P/EBITDA

3.01

Sector -19.62

Industry -19.62

P/EBIT

4.17

Sector -65.94

Industry -65.94

P/Total Assets

0.24

Sector 1.04

Industry 1.04

P/Net Current Assets

-0.71

Sector -9.57

Industry -9.57

P/Working Capital

1.58

Sector -123.00

Industry -123.00

EPS

0.77

Sector -1.81

Industry -1.81

BVPS

13.50

Sector 1.95

Industry 1.95

Efficiency

Gross Margin

37.00%

Sector 40.72%

Industry 40.72%

EBITDA Margin

23.27%

Sector -21,198.78%

Industry -21,198.78%

EBIT Margin

16.25%

Sector -35.70%

Industry -35.70%

Net Profit Margins

6.10%

Sector -36.09%

Industry -36.09%

Asset Turnover

0.09

Sector 0.03

Industry 0.03

Profitability

ROE

5.87%

Sector -59.44%

Industry -59.44%

ROA

2.29%

Sector -60.14%

Industry -60.14%

ROIC

5.19%

Sector -1,846.72%

Industry -1,846.72%

Dividends

Dividend yield

0.93%

Sector -

Industry -

Payout

9.85%

Sector -

Industry -

Debt

Current Ratio

2.37

Sector 2.91

Industry 2.91

Net Debt / EBITDA

4.13

Sector -20.38

Industry -20.38

Net Debt / EBIT

5.71

Sector -4.13

Industry -4.13

Net Debt / Equity

0.83

Sector -33,112.98

Industry -33,112.98

Gross Debt / Equity

0.90

Sector -0.64

Industry -0.64

Equity/Assets

0.40

Sector 0.45

Industry 0.45

Liabilities/Assets

0.60

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

23.22%

Sector -

Industry -

5Y Earnings CAGR

10.52%

Sector -

Industry -

Fundamentals GRFS

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Grifols ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$8.20

Fair Value

$15.29

Upside

86.62%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
GRFS Grifols S.A.	$8.20	-11.77%	0.93%	10.59	0.61	5.87%	6.10%
PFE Pfizer Inc.	$30.44	36.07%	5.73%	39.46	2.00	4.97%	6.80%
ABBV AbbVie Inc.	$295.11	35.26%	2.31%	53.66	0.00	-%	14.76%
NVO Novo Nordisk A/S	$39.80	-16.51%	4.76%	9.52	5.05	53.11%	35.32%
MRK Merck & Co. Inc.	$149.46	77.69%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$187.27	15.68%	1.73%	22.38	5.77	27.27%	16.95%
ZTS Zoetis Inc.	$80.24	-43.19%	2.58%	12.83	10.75	83.77%	27.69%
AMGN Amgen Inc.	$469.71	66.32%	2.13%	28.86	21.58	91.47%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$912.86	40.12%	0.41%	21.68	2.96	14.04%	27.86%
HALO Halozyme Therapeutics Inc.	$130.85	100.51%	0.00%	37.10	106.90	173.67%	24.86%
MCK McKesson Corporation	$1,005.04	25.05%	0.34%	26.09	-31.01	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$559.48	34.10%	0.00%	30.31	6.59	21.76%	35.00%
CAH Cardinal Health Inc.	$253.37	55.51%	0.81%	34.72	-21.85	-62.92%	0.67%
ARGX argenx SE	$905.64	10.18%	0.00%	13.26	-	-%	25.42%
HRMY Harmony Biosciences Holdings Inc.	$38.76	32.20%	0.00%	12.39	2.25	20.46%	18.88%
BIIB Biogen Inc.	$254.75	72.29%	0.00%	45.08	2.00	4.58%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

GRFS - Historical Dividends

Current Dividend Yield

0.93%

5-year average Dividend Yield

1.18%

Current Payout

9.85%

5-year average Payout

7.07%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	07/01/2026	07/09/2026	0.07650000
Dividends	08/11/2025	08/20/2025	0.17340000
Dividends	06/02/2021	06/14/2021	0.43850000
Dividends	10/29/2020	11/09/2020	0.20140000
Dividends	11/29/2019	12/11/2019	0.22190000
Dividends	06/06/2019	06/18/2019	0.16420000
Dividends	11/29/2018	12/11/2018	0.22780000
Dividends	05/31/2018	06/12/2018	0.25100000
Dividends	11/30/2017	12/12/2017	0.21270000
Dividends	05/30/2017	06/08/2017	0.16330000
Dividends	12/05/2016	12/14/2016	0.19340000
Dividends	06/02/2016	06/15/2016	0.16190000
Dividends	12/10/2015	12/17/2015	0.19220000
Dividends	06/08/2015	06/15/2015	0.16560000
Dividends	12/04/2014	12/12/2014	0.15450000
Dividends	06/05/2014	06/13/2014	0.14350000
Dividends	06/05/2013	06/13/2013	0.13040000
Dividends	05/24/2013	06/05/2013	0.006500

ABOUT Grifols

Grifols S.A.

Average Investor10 user rating

4.0 (4 people)

United States

39 years

Founded: 1987

2011

Time since IPO - 15 years

23.655

Employees

Grifols S.A. (United States) is listed on the Nasdaq and has a market capitalization of $5.58 billion, with shareholders equity totaling $9.19 billion.

The company employs approximately 23.655 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Grifols S.A. reported $8.63 billion in revenue, generating net income of $527.03 million.

Key financial metrics include a P/E ratio of 10.59, a price-to-book (P/B) ratio of 0.61, and a trailing twelve-month dividend yield of 0.93%.

The company trades under the ticker GRFS.

Market cap

$5.58 billion

Net worth

$9.19 billion

$9,193,550,000.00

Assets

$23.15 billion

$23,145,160,000.00

Total Shares Outstanding

681.00 million

681,000,000

Average Daily Trading Volume

$577.37 Thousand

$577,372.00

Sector

Health Care

Industry

Biotechnology

GRFS

GRFS revenue and profits

Financial Results GRFS

DRAG THE FRAME TO SEE MORE DATA

GRFS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,005.04 24,48% (12M)

P/E

26.09

0.34%

ROE

-118.84%

P/BV

-31.01

CAH - Cardinal Health

$253.37 34,07% (12M)

P/E

34.72

0.81%

ROE

-62.92%

P/BV

-21.85

ABBV - AbbVie

$295.11 39,67% (12M)

P/E

53.66

2.31%

ROE

P/BV

0.00

MRK - Merck & Co.

$149.46 78,93% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$187.27 16,56% (12M)

P/E

22.38

1.73%

ROE

27.27%

P/BV

5.77

PFE - Pfizer

$30.44 32,16% (12M)

P/E

39.46

5.73%

ROE

4.97%

P/BV

2.00

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,005.04 24,48% (12 M)

P/L

26.09

0.34%

ROE

-118.84%

P/VP

-31.01

CAH - Cardinal Health

$253.37 34,07% (12 M)

P/L

34.72

0.81%

ROE

-62.92%

P/VP

-21.85

ABBV - AbbVie

$295.11 39,67% (12 M)

P/L

53.66

2.31%

ROE

P/VP

0.00

MRK - Merck & Co.

$149.46 78,93% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$187.27 16,56% (12 M)

P/L

22.38

1.73%

ROE

27.27%

P/VP

5.77

PFE - Pfizer

$30.44 32,16% (12 M)

P/L

39.46

5.73%

ROE

4.97%

P/VP

2.00

BMY - Bristol-Myers Squibb

Frequently Asked Questions

What is the price of Grifols (GRFS) today?

The current price of Grifols (GRFS) is $8.20. The stock began the year trading around $9.35 and is currently priced at $8.20. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Grifols (GRFS) pay dividends?

In the last year, Grifols (GRFS) distributed dividends in the month of July, totaling $0.08. The Dividend Yield for the last 12 months is 0.93%.

Is Grifols (GRFS) a good investment?

Grifols (GRFS) is currently trading at $8.20 with a P/E ratio of 10.59. This represents a 2,712% premium compared to its historical average P/E. Over the past year, the stock paid $0.08 in dividends, resulting in a dividend yield of 0.93%. The total shareholder return over the same period was -11.58%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Grifols (GRFS) stock?

You can buy Grifols (GRFS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol GRFS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Grifols (GRFS) yield today?

Over the past month, Grifols (GRFS) has returned 12.11% — -11.58% over the past year, and -35.66% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.08 per share in dividends, resulting in a dividend yield of 0.93%.

If you were to purchase 100 shares of Grifols (GRFS) today at the current price of $8.20 your total investment would be $819.50.

Based on historical performance, the investment would have grown to approximately:

$724.60 after 1 year
$527.27 after 5 years
$532.18 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

GRFS

Grifols S.A.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment GRFS

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING GRFS WITH OTHER STOCKS

type

Ex - Dividend Date

payment date

value

ABOUT Grifols

Grifols S.A.

United States

39 years

2011

23.655

PROFIT X PRICE GRFS

Financial Results GRFS

GRFS cash flow

Asset, Revenue and Profit Growth - GRFS

GRFS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions